CA1339015C - Macrocyclic chelates and methods of use thereof - Google Patents
Macrocyclic chelates and methods of use thereofInfo
- Publication number
- CA1339015C CA1339015C CA000600714A CA600714A CA1339015C CA 1339015 C CA1339015 C CA 1339015C CA 000600714 A CA000600714 A CA 000600714A CA 600714 A CA600714 A CA 600714A CA 1339015 C CA1339015 C CA 1339015C
- Authority
- CA
- Canada
- Prior art keywords
- group
- chelate
- member selected
- conjugate
- integer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/534—Production of labelled immunochemicals with radioactive label
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Abstract
The invention is a chelate having a general formula wherein R1-4 is -CH2COOH;
n is 1 to 5;
X is a member selected from the group consisting of -N02, -NH2, -NCS, -NHCOCH2 - Z with Z being a member selected from the group consisting of Br and I;
-COOH; and -OCH200CH;
and M is a metal ion being a member selected from the group of elements consisting of Bi, Pb, Y, Cd, Hg, Al, Th, Sr, and Lanthanides. The invention can include a chelate wherein M is a copper ion and n is an integer from 2 to 5. The invention includes chelate conjugates of formula I and ligand conjugates of formula II:
n is 1 to 5;
X is a member selected from the group consisting of -N02, -NH2, -NCS, -NHCOCH2 - Z with Z being a member selected from the group consisting of Br and I;
-COOH; and -OCH200CH;
and M is a metal ion being a member selected from the group of elements consisting of Bi, Pb, Y, Cd, Hg, Al, Th, Sr, and Lanthanides. The invention can include a chelate wherein M is a copper ion and n is an integer from 2 to 5. The invention includes chelate conjugates of formula I and ligand conjugates of formula II:
Description
133~015 FUNCTIONALIZED TETRAAZACYCLODODECANE-BASED CHELATES
BACKGROUND OF THE INVENTION
1. Field of the Invention This invention relates to macrocyclic chelates and methods of use thereof. More specifically, this invention relates to 2-substituted 1, 4, 7, 10-tetraazacyclododecane -N, N', N", N"'-tetraacetic acid, 2-substituted 1, 4, 7, 10-tetraazacyclododecane, and analog macrocycles and their uses.
BACKGROUND OF THE INVENTION
1. Field of the Invention This invention relates to macrocyclic chelates and methods of use thereof. More specifically, this invention relates to 2-substituted 1, 4, 7, 10-tetraazacyclododecane -N, N', N", N"'-tetraacetic acid, 2-substituted 1, 4, 7, 10-tetraazacyclododecane, and analog macrocycles and their uses.
2. Description of the Back~round Art Macrocycles have been studied for their usefulness as chelates for numerous metal ions that have therapeutic, diagnostic, or other uses. A macrocycle of particular usefulness as a chelate is the 1, 4, 7, 10-tetraazacyclododecane -N, N', N", N"'-tetraacetic acid (DOTA). DOTA compounds have been linked to biomolecules to form delivery systemsfor the chelated metal ion to specific sites within an organism.
2 l 33901 5 U.S. Patent No. 4,678,667 to Meares et al., discloses a macrocyclic, bifunctional chelating agent. The chelating agents of this disclosure can include DOTA compound that is a Cu(II) chelate. The usefulness of the chelating agent is limited to the effects of the copper metal ion. The synthesis of this disclosure gives low and not always reproducible results.
U.S. Patent No. 4,622,420, an earlier patent, to Meares et al., disclosed bifunctional chelating agents of the acyclic ligand, ethylene ~ mine N, N', N", N"' tetraacetic acid (EDTA), useful for binding metals other than copper, such as Indium. These compounds are useful for im~ging of tumors.
U.S. Patent No. 4,652,519 to Warshawsky et al. discloses bifunctional chelating agents and precess for their production. The compounds disclosed in this patent are analogues of EDTA. These compounds are used to chelate metal ions and are linked to haptens to provide specific site selection within an organism. The compounds of this patent are offered to providc an improved substituent for the EDTA compounds, such as those disclosed in the Meares et al. patent discussed above.
U.S. Patent Nos. 4,454,106 and 4,472,509 to Gansow et al., disclose the use of metal chelate-conjugated monoclonal antibodies and the specific metal chelate-conjugated monoclonal antibodies, respectively. These disclosures provide compounds and methods for treating cellular disorders. Radiometal chelate-conjugated monoclonal antibodies specific to a target cell are used to deliver alpha, beta, or Auger electron emitting metal ions. These disclosures are not related to DOTA compounds.
. 5~
2 l 33901 5 U.S. Patent No. 4,678,667 to Meares et al., discloses a macrocyclic, bifunctional chelating agent. The chelating agents of this disclosure can include DOTA compound that is a Cu(II) chelate. The usefulness of the chelating agent is limited to the effects of the copper metal ion. The synthesis of this disclosure gives low and not always reproducible results.
U.S. Patent No. 4,622,420, an earlier patent, to Meares et al., disclosed bifunctional chelating agents of the acyclic ligand, ethylene ~ mine N, N', N", N"' tetraacetic acid (EDTA), useful for binding metals other than copper, such as Indium. These compounds are useful for im~ging of tumors.
U.S. Patent No. 4,652,519 to Warshawsky et al. discloses bifunctional chelating agents and precess for their production. The compounds disclosed in this patent are analogues of EDTA. These compounds are used to chelate metal ions and are linked to haptens to provide specific site selection within an organism. The compounds of this patent are offered to providc an improved substituent for the EDTA compounds, such as those disclosed in the Meares et al. patent discussed above.
U.S. Patent Nos. 4,454,106 and 4,472,509 to Gansow et al., disclose the use of metal chelate-conjugated monoclonal antibodies and the specific metal chelate-conjugated monoclonal antibodies, respectively. These disclosures provide compounds and methods for treating cellular disorders. Radiometal chelate-conjugated monoclonal antibodies specific to a target cell are used to deliver alpha, beta, or Auger electron emitting metal ions. These disclosures are not related to DOTA compounds.
. 5~
`1 The value of having a ligand conjugate to chelate 2 metal ions for therapeutic, diagnostic, or other uses is 3 of commercial importance. This commercial importance is 4 created by the fact that many metal ions have desirable characteristics for these various uses, but the delivery 6 systems for the metal ions lack specificity to target 7 cells or do not adequately bind the metal ions. ~xamples 8 of the usefulness of specific metal ions are as follows.
9 The usefulness of radionuclide materials in cancer therapy is disclosed in the article, Kozak et al., 11 "Radionuclide-conjugated monoclonal antibodies: A
12 Synthesis of Immunology, in Organic Chemistry and ~luclear 13 Science', Trends in Biotechnology 4(10):259-264 (1985).
14 This article discusses the use of antibody conjugates to deliver either alpha or beta radiation. The value of 16 alpha radiation from bismuth-212 in radionuclide therapy 17 is further discussed in the two articles, Kozak et al.
18 "Bismuth-212-labeled anti-Tac monoclonal antibody:
19 Alpha-particle-emitting Radionuclides as Modalities for Radioimmunotherapy', Proc. Natl. Acad. Sci. U.S.A.
21 83:474-478 (1986) and Gansow et al., "Generator-produced 22 Bi-212 Chelated to Chemically Modified Monoclonal 23 Antibody for Use in Radiotherapy" Am. Chem. So.
24 Symposium Series 15:215-227 (1984).
~xamples of other uses for chelated metal ions are 26 disclosed in the following articles. Magerstadt et al., 27 "Gd(DOTA): An Alternative to Gd(DPTA) as a Tl 2 28 Relaxation Agent for NMR Imaging or Spectroscopy", 29 ~Iagnetic Resonance in Medicine 3:808-812 (1986), discloses the usefulness of gadolinium as a relaxation 31 agent for NMR imaging. The article, Spirlet et al., 32 "Structural Characterization of a Terbium(III) Complex 33 w;th 1, 4, 8, ll-Tetraazacyclotetradecane- 1, 4, 8, 1 ll-tetraacetic Acid. Lanthanide Ions and the 2 Conformation of the 14-Mem~ered Macrocycles",Inorganic 3 Chemistry 23(25):4278-4283 (1984), discloses the 4 usefulness of lanthanide chelates.
The industry is lacking a DOTA chelate that can be 6 efficiently produced in high yields and that has 7 desirable chelating qualities for numerous metal ions.
8 SU~RY OF THE INV~NTION
9 The invention is a chelate of formula I:
~R.
Al ~ R, 11 wherein Rl_4 is -CH2COOH;
12 n is 1 to 5;
13 X is a member selected from the group consisting of 14 -N02, -NH2, 16 -NCS, 17 -NHCOCH2 - Z,with Z being a member selected from the 18 group consisting of Br and I, 19 -COOH, and -OCH2COOH;
21 and M is a metal ion being a member selected from the 22 group of elements consisting of 23 Bi, Pb, Y, Cd, Hg, Ac, Th, Sr, and Lanthanides.
9 The usefulness of radionuclide materials in cancer therapy is disclosed in the article, Kozak et al., 11 "Radionuclide-conjugated monoclonal antibodies: A
12 Synthesis of Immunology, in Organic Chemistry and ~luclear 13 Science', Trends in Biotechnology 4(10):259-264 (1985).
14 This article discusses the use of antibody conjugates to deliver either alpha or beta radiation. The value of 16 alpha radiation from bismuth-212 in radionuclide therapy 17 is further discussed in the two articles, Kozak et al.
18 "Bismuth-212-labeled anti-Tac monoclonal antibody:
19 Alpha-particle-emitting Radionuclides as Modalities for Radioimmunotherapy', Proc. Natl. Acad. Sci. U.S.A.
21 83:474-478 (1986) and Gansow et al., "Generator-produced 22 Bi-212 Chelated to Chemically Modified Monoclonal 23 Antibody for Use in Radiotherapy" Am. Chem. So.
24 Symposium Series 15:215-227 (1984).
~xamples of other uses for chelated metal ions are 26 disclosed in the following articles. Magerstadt et al., 27 "Gd(DOTA): An Alternative to Gd(DPTA) as a Tl 2 28 Relaxation Agent for NMR Imaging or Spectroscopy", 29 ~Iagnetic Resonance in Medicine 3:808-812 (1986), discloses the usefulness of gadolinium as a relaxation 31 agent for NMR imaging. The article, Spirlet et al., 32 "Structural Characterization of a Terbium(III) Complex 33 w;th 1, 4, 8, ll-Tetraazacyclotetradecane- 1, 4, 8, 1 ll-tetraacetic Acid. Lanthanide Ions and the 2 Conformation of the 14-Mem~ered Macrocycles",Inorganic 3 Chemistry 23(25):4278-4283 (1984), discloses the 4 usefulness of lanthanide chelates.
The industry is lacking a DOTA chelate that can be 6 efficiently produced in high yields and that has 7 desirable chelating qualities for numerous metal ions.
8 SU~RY OF THE INV~NTION
9 The invention is a chelate of formula I:
~R.
Al ~ R, 11 wherein Rl_4 is -CH2COOH;
12 n is 1 to 5;
13 X is a member selected from the group consisting of 14 -N02, -NH2, 16 -NCS, 17 -NHCOCH2 - Z,with Z being a member selected from the 18 group consisting of Br and I, 19 -COOH, and -OCH2COOH;
21 and M is a metal ion being a member selected from the 22 group of elements consisting of 23 Bi, Pb, Y, Cd, Hg, Ac, Th, Sr, and Lanthanides.
The invention can include a chelate, wherein M is a copper ion and n is an integer from 2 to 5. The invention includes chelate conjugates of formula I and ligand conjugates of formula II~
` 'L~
The invention also includes methods to use these compounds for treatment of cellular disorders and for diagnostic tests for same.
BRIEF DESCRIPTION OF THE DRAWINGS
Figures lA and lB illustrate a chemical pathway to produce the preferred embodiment of the invention. In the detailed description, reference is made to Figure 1, but it is to be noted that Figures lA and lB provide a schematic of a continuous reaction scheme.
DETAILED DESCRIPTION OF THE INVENTION
The compound of this invention is a substituted DOTA represented by formula l, shown above or specifically by compound 10 of Figure 1. Compound 10 can subsequently be converted to other substituted DOTA compounds, but compound 10 is the parent compound for such other compounds. The general formula is a 12 membered ring tetraaza macromolecule with the nitrogens in the 1, 4, 7, and 10 positions. Each of the nitrogens is "ribbed" by an ethylene group.
The substituted DOTA ligand represented by compound 10 of Figure 1 complexes metals. Metal complexes are formed by placing the DOTA into solution with an appropriate metal salt having the metal to be chelated. Metal salts ~, 6 1 339û 1 5 have to be selected so as to prevent the hydrolysis of the metal. Also, reaction conditions in an aqueous medium have to be chosen such that the metal is not hydrolyæd. Forexample, a lead nitrate complex, bismuth iodide complex, or yttrium acetate salts can be used to form a metal chelate with lead, bismuth, or yttrium, respectively. General examples of suitable salts include any soluble divalent metal complex or any trivalent metal complex that is not hydrolyzed at pH 4 or below. Thorium requires the use of iodide salt, specifically. The most desirable metal ions for chelation with formula 1 are members from the group consisting of bismuth, lead, yttrium, cadmium, mercury, actinium, thorium, strontium, and any of the elements of the l~nth~nide elements. The most desirable elements of the l~nth~nide series are gadolinium, for use in NMR im~ging and as a relaxation agent in NMR im~ging, and terbium and europium, because of their use as chromophores in time-resolved fluorescence spectroscopy. These fluorescent compounds can be useful in an in vitro diagnostic assay, where a fluorescent assay is used, rather than a radioactive amino assay.
The X substituent of formula is desirably a substituent that conjugates the compound with haptens. This substituent is desirably a free-end nitro group, which can be reduced to an amine. The amine can then be activated with a compound, such as thionyl chloride, to form a reactive chemical group, such as an isothiocyanate. An isothiocyanate is preferred because it links directly to amino residues of a hapten, such as a monoclonal antibody. The amiline group can be linked to an oxidized carbohydrate on the protein and, subsequently, the linkage fixed by reduction with cyanoborohydride. The amino group then can also be reacted with bromoacetyl chloride or iodoacetyl chloride , to form -NHCOCH2Z with Z being bromide or iodide. This group reacts with any available amine or sulfhydryl group on a hapten to form a stable covalent bond. If tyrosine is used in the formulation of the macromolecule, a carboxylic acid or methoxy carboxylate group can be in this position of the compound. The most desirable substituents for this position are members selected from the group consisting of -NO2, NH2, -NCS, -COOH, -OCH2COOH, -OCH2COOH and -NHCOCH2-Z, with Z being a member selected from the group consisting of bromide and iodide. The preferred substituent for this position is -NCS.
The haptens suitable for linking with the substituent at the X position of formula 1 can vary widely. The most desirable haptens are members selected from the group consisting of hormones, steroids, enzymes, and proteins. These haptens are desirable because of their site specificity to tumors and/or various organs of the body. The preferred hapten for use in treating cellular disorders or various disease conditions is a monoclonal antibody.
The compound of this invention can have n equal an integer from 1 to 5. In the preferred embodiment, M equals 2. It is desirable for n to equal 2 versus 1 because the chelating ligand is further separated from the antibody and has more rotation. The increased free rotation allows a metal to chelate with the macromolecule more easily.
When n is 3 or greater, the synthesis of the compound becomes lengthy.
Figure 1 illustrates the plcr~llcd reaction pathway or process for forming the compound of this invention. This reaction results in a compound of formula 1, wherein n is 1. If n is to equal 2, an additional methylene group would be present between the alpha amino carbon and the aromatic group. This compound is 2-amino-4-nitrophenylbutyric acid.
The process for synthesizing a compound according to this invention first provides a triamine with a substituent is in the 2-position. The embodiment of Figure 1 has a methylene [n = 1] as the initial substituent for linkage. The preferred embodiment has a phenyleythylene group. The process then provides a tetraaza macromolecule having the substituent in the 2 position. Alkylation with bromoacetic acid forms the four carbon to nitrogen bonds of the carboxymethylene substituents at the R1, R2, R3, and R4 in formula I.
The process of Figure 1 reacts p-nitrophenyl alanine with methanol and hydrochloric acid to form the ester compound 2. This ester is reacted with ethylene~ mine in the presence of triethylamine to remove the hydrochloride salt of the ester formed in the compound. The con(lçn~te of the amide of the ethylene~ mine adduct or compound 3 is subsequently reacted with a diactive ester or compound 6 to form a cyclic product or compound 7.
The desired diactive ester 6 is formed sequentially from amidodiacetic acid for 4 of Figure 1. The amine is first blocked by using the reagent BOC-ON or any other suitable blocking agent, such as FMOC, in the presence of triethylamine which serves to deprotonate the starting material. The subsequent nitrogen-blocked diacetic acid 5 other such nitrogen-blocked compound is then coupled to N-hydroxysuccinimide, or any other suitable compound, such as phenols, or N-hydroxydicarboximides which forms a g reaction ester. The choice of compounds which form active esters or blocking groups is within the scope of the art. The coupling is done by dicyclohexyl-carbodiimide or "DCC".
This step produces the nitrogen-blocked active ester or compound 6.
Ring fommation under high dilution conditions between amino acidamide or compound 3 with the nitrogen-blocked active ester of compound 6 then occurs. This condensing step forms the triamide macrocycle or compound 7. Compound 7 is produced in very high yield. The yield is typically at least about 80 percent. The yield more desirably is between about 80 percent to about 95 percent.
The synthesis of the macrocycle of compound 7 may be accomplished by two pathways. The amine nitrogen of compound 7 is deblocked with trifluoroacetic acid or "TFA". This forms the TFA salt of the triamide macrocycle or compound 8. This compound is reduced with borane/tetrahydrofuran or THF. The resulting borane adduct is cleaved by hydrochloric acid to form the substituted tetr~:~7~m~crocycle of compound 9.
This tetr~7~m~crocycle can then be alkylated with haloacetic acid in the presence of base to fomm a nitroben_yl DOTA or compound 10. Altematively, compound 7 can be reduced with borane/THF and reacted with hydrochloric acid to form compound 9 directly. This altemative pathway produces a slightly poorer yield.
The nitro group of compound 10 can be reduced with hydrogen over pl~tinllm on a carbon catalyst to produce the amino group or the aminoben_yl DOTA depicted as 1 33~0 1 5 compound 11. Compound 11 can then be reacted with thiophosgene to produce the isothiocyanate or compound XII.
The methodology in colurnn 3 of U.S. Patent No. 4,652,519 to Warshawsky et al., provides the methodology to produce the -COOH substituent. This procedure produces the ethylene ~ mine intermediate. The desired intermediate macrocycle is produced by forming the analogous diactive ester of compound 6 by using N, N'-ethylenediaminediacetic acid. Condensation of the ~ rnine with the dinitrogen, diBOC
diactive ester produces diamide intermediary, which is reduced by diborane to produce the ~plo~liate tetraaza macrocycle. The DOTA ligand can be made from this macrocycle.
The synthesis of the X and Z groups are also disclosed by the Warshawsky et al. patent.
The reaction steps described above to produce compounds 10, 11, and 12 are known. The novel feature of the process of Figure 1 is the cyclization procedure. The conversation reaction of compound 4 with compound 6 to form the macrocycle and the full reduction of the macrocycle to produce compound 10 produces the unexpected results of very high yields compound 10.
In its preferred embodiment the coupling of an isothiocyanate chelate of compound 12 of Figure 1 is done by direct conjugation of the isothiocyanate with a free amino group found in many residues of proteins, enzymes or other compounds such as certain hormones. An example of this situation with a hormone is found with the free amino group provided by the epsilon amino group of the lysine or the terminal amino group as the hormone peptide chain. Any free amino group can react with the isothiocyanate to form a thiourea linkage, which is covalently coupled and irreversible. The use of a steroid as a hapten requires that an amino function be present in the steroid.
An advantage of the amine derivative chelate of compound 11 of Figure 1 is that,when coupling to proteins and, in particular, when coupling to antibodies, the carbohydrate of the antibody can be oxidized prior to the coupling reaction. The amine reacts with the aldehyde that is formed on the protein. This aldimine formed can be reduced by cyanoborohydride to form a covalent secondary amine linkage to the antibody in a position that is site-specific. This position is away from the binding site of the FAB'2 part of the monoclonal antibody.
A desirable embodiment of the invention is one having copper metal ion and n is an integer from 2 to 5. This embodiment of the invention can be used to label a monoclonal antibody with Cu67. When n is an integer from 2 to 5, there is less hindrance of the chain of the ligand with the protein than occurs when n is 1. When n is an integer from 2 to 5, sufficient space is provided between the ligand and the protein to allow freer rotation of the ligand. This results in more efficient chelation of the copper ion by the resulting conjugate.
An embodiment of the invention involves a ligand-hapten conjugate of formula 2:
.
'~
Fd. ,~
l .~-- ,~ `I
A . ~ ~
This conjugate chelates metal ions. It is desirable to expose many metals to the protein conjugate in a concentrated metal solution for as short a period of time as possible.
Certain metals, such as divalent metal ions, react rapidly and directly with the conjugate.
The kinetics of the formation reactions for these compounds are so rapid that it is desirable to have the ligand-hapten conjugate available in the pharmacy immediately prior to use.
The conjugate can then be mixed in the radionuclide to form a complex and, subsequently, the metal chelate conjugate formed can be purified by, for example, size exclusion high pressure liquid chromatography. A desirable hapten for the ligand conjugate can be selected from the group consisting of hormones, steroids, enzymes, and proteins.The most commercially useful embodiments of the invention are chelate conjugateshaving formula 1, wherein (1) n is an integer from 1 to 5, (2) X' is a member selected from the group consisting of -NHQ, -NCS-Q, -NHCOCH2-Q, -OCH2COOQ, and -COO-Q
with Q being a hapten selected from the group consisting of hormones, steroids, enzymes, and proteins, and (3) M is a metal ion being a member selected from the group ofelements consisting of Bi, Pb, Y, Cd, Hg, Ac, Th, Sr, and L~nth~nides. These chelates conjugates can deliver radioactive metal ions, such as Pb2l2, Bi2l2, Y90, Th224, and Sr90, to specific cellular disorders.
The preferred embodiment of the invention uses a chelate conjugate binding Pb2l2.
Pb2l2 is a very desirable ph~rm~reutical compound for delivering both beta and alpha radiation to a selected site for treatment of the cellular disorders. The delivery is made through the Pb2'2 ion, which converts with a 10 1/2 hour half-life into Bi2l2. Bi2l2 and ~ ghtf~rs deliver one alpha particle per Pb2l2 nucleus. The desirable result of this chelate conjugate is that the Pb2'2 half-life is sufficient to allow site selection from the body fluid by the hapten before the alpha particle is emitted.
The invention includes a process for treating cellular disorders. This process uses the chelate conjugate with a hapten having a selective binding site at the cellular disorder.
For example, Q can be a monoclonal antibody, wherein the antibody is directed and created against an epitope found specifically on the tumor cells. Thus, when Pb2~2 is transported to the antegen site and, subsequently, decays in secular equilibrium to Bi2l2 and its ~ ghters, a beta irradiation is produced from the lead disintegration. A beta radiation is produced by the bismuth ~ lght~rs. This beta radiation is similar to the beta radiation from Y90 but, in addition, each disintegration of bismuth also produces an alpha particle.
In this manner, a radiotherapy is provided with a radiation dose from both an alpha and a beta particle. If desired, only Bi2l2 can be introduced in those cases where the disorder to be treated, such as with leukemic cells, can be easily reached within the 1 hour half-life of Bi2'2. It is also possible to use this method to treat cancers, where the cells are widely differentiated. This might be preferred where only a long range beta-emitter, such as Y90, is desired. In differing environments, in vivo, the Bi2l2 is retained inside the chelate after the beta emission in differing amounts. Most desirably, at least 95 percent of Bi2l2 remains in the chelate. In an acidic medium, such as the stomach, at least about 70 percent of the . ,~
-14- l 339U 1 5 Bi212 is retained. Retaining at least about 80 or 90 percent, Bi2~2 is also desirable depending on the medium.
The invention includes a process for diagnostic testing. This process uses a chelate conjugate having formula I wherein M is a member selected from the group consisting of Pb , Tc , In ", Ga67, Ga6x, Sc43, Sc44 Fe52 Fe54 Fe56 Fe57 Fe58 d C 55 usefulness of metal ions with both in vitro and in vivo diagnostic procedures is disclosed in U.S. Patent No. 4,454,106.
The most desirable embodiment of this diagnostic process uses Pb203. Pb203 has a52.1 hour half-life as a gamma emitter. Pb203 has a unique property in that it decays at a high percentage only by a single photon emission. This gamma emission is preferred and dominant over all other emissions. This single photon emission makes Pb203 useful for single photon emission computed spectroscopy [SPECT], which is a diagnostic tool. Thus, when Pb203 is linked by use of the chelate to a hapten, which specifically localizes in a tumor, then that particular localization can be three dimensionally mapped for diagnostic purposes in vivo by single photon emission tomography. Alternatively, the emission can be used in vitro in radioimmunoassays.
The procedures and reagents described above for the preferred embodiment of making the compounds are used for this example.
-15- l 33 90 1 5 The antibody specific for the IL-2 antigen is the monoclonal antibody alpha-Tac.This antibody is labelled with the chelate of compound 12 of Figure 1 as follows. The antibody is suspended in a buffered normal saline solution having a pH of about 8.5.
Solid ligand or compound 12 is added to the protein suspension. The protein conjugate forms during reaction overnight and is purified by dialysis against metal-free 0.05 molar citrate/0.15 molar sodium chloride buffer at pH 5.5. Before labelling with metal, the protein is dialyzed against a solution comprising 0.02 molar N-morpholinoethanesulfonic acid and 0.02 molar acetate at pH 5.9.
The protein in solution is labelled with Y90 by reacting with an acetate solution of the isotope followed by passage through a TSK 3000 size exclusion column. This is a high pressure liquid chromotography procedure. The compound is mixed with a pharmaceutical excipient and is used in m~mm~l~ in a therapeutic amount to treat adult T-cell leukemia in m~mm~l~. T-cell leukemia is characterized by extraordinarily large amounts of IL-2 receptors on the tumor cells. The antibody localizes specifically to these tumor cells to deliver its radiation.
EXAMPLES 2 and 3 The procedures and reagents described above for the plefelled embodiment of making the compounds are used for these examples. The only difference between Example 1 and Examples 2 and 3 is the use of the antibody B72.3, which binds specifically to a glycoprotein on LS-174T cells. This glycoprotein is also in humans, who have colon cancer. The model system of this example is an -16- l 3390 1 5 athymic mouse, into which has been implanted LS-174T cells to develop a tumor on the flank of the animal where the cells were implanted. The diagnostic method used to visualize the growing tumor involves the following components. The chelate of compound 12 is first coupled to gadolinium or Pb203 by mixture of the chelate solution at pH 4 to 5 with gadolinium or Pb203 nitrate. This material can be then linked directly to the antibody by mixture to react with the protein and purified according to the method of the previous example.
In Example 2, the gadolinium chelate ligand-protein conjugate is injected or introduced into body fluids of a m~mm~l. The gadolinium then localizes along with the antibody to the tumor and conventional resonance magnetic im:~ging techniques are used to visualize the tumor.
In Example 3, Pb203 is used and the metal-labelled protein conjugate is similarly introduced into the m~mm~l, but gamma camera or SPECT im~gin~ is used to visualize the tumor.
` 'L~
The invention also includes methods to use these compounds for treatment of cellular disorders and for diagnostic tests for same.
BRIEF DESCRIPTION OF THE DRAWINGS
Figures lA and lB illustrate a chemical pathway to produce the preferred embodiment of the invention. In the detailed description, reference is made to Figure 1, but it is to be noted that Figures lA and lB provide a schematic of a continuous reaction scheme.
DETAILED DESCRIPTION OF THE INVENTION
The compound of this invention is a substituted DOTA represented by formula l, shown above or specifically by compound 10 of Figure 1. Compound 10 can subsequently be converted to other substituted DOTA compounds, but compound 10 is the parent compound for such other compounds. The general formula is a 12 membered ring tetraaza macromolecule with the nitrogens in the 1, 4, 7, and 10 positions. Each of the nitrogens is "ribbed" by an ethylene group.
The substituted DOTA ligand represented by compound 10 of Figure 1 complexes metals. Metal complexes are formed by placing the DOTA into solution with an appropriate metal salt having the metal to be chelated. Metal salts ~, 6 1 339û 1 5 have to be selected so as to prevent the hydrolysis of the metal. Also, reaction conditions in an aqueous medium have to be chosen such that the metal is not hydrolyæd. Forexample, a lead nitrate complex, bismuth iodide complex, or yttrium acetate salts can be used to form a metal chelate with lead, bismuth, or yttrium, respectively. General examples of suitable salts include any soluble divalent metal complex or any trivalent metal complex that is not hydrolyzed at pH 4 or below. Thorium requires the use of iodide salt, specifically. The most desirable metal ions for chelation with formula 1 are members from the group consisting of bismuth, lead, yttrium, cadmium, mercury, actinium, thorium, strontium, and any of the elements of the l~nth~nide elements. The most desirable elements of the l~nth~nide series are gadolinium, for use in NMR im~ging and as a relaxation agent in NMR im~ging, and terbium and europium, because of their use as chromophores in time-resolved fluorescence spectroscopy. These fluorescent compounds can be useful in an in vitro diagnostic assay, where a fluorescent assay is used, rather than a radioactive amino assay.
The X substituent of formula is desirably a substituent that conjugates the compound with haptens. This substituent is desirably a free-end nitro group, which can be reduced to an amine. The amine can then be activated with a compound, such as thionyl chloride, to form a reactive chemical group, such as an isothiocyanate. An isothiocyanate is preferred because it links directly to amino residues of a hapten, such as a monoclonal antibody. The amiline group can be linked to an oxidized carbohydrate on the protein and, subsequently, the linkage fixed by reduction with cyanoborohydride. The amino group then can also be reacted with bromoacetyl chloride or iodoacetyl chloride , to form -NHCOCH2Z with Z being bromide or iodide. This group reacts with any available amine or sulfhydryl group on a hapten to form a stable covalent bond. If tyrosine is used in the formulation of the macromolecule, a carboxylic acid or methoxy carboxylate group can be in this position of the compound. The most desirable substituents for this position are members selected from the group consisting of -NO2, NH2, -NCS, -COOH, -OCH2COOH, -OCH2COOH and -NHCOCH2-Z, with Z being a member selected from the group consisting of bromide and iodide. The preferred substituent for this position is -NCS.
The haptens suitable for linking with the substituent at the X position of formula 1 can vary widely. The most desirable haptens are members selected from the group consisting of hormones, steroids, enzymes, and proteins. These haptens are desirable because of their site specificity to tumors and/or various organs of the body. The preferred hapten for use in treating cellular disorders or various disease conditions is a monoclonal antibody.
The compound of this invention can have n equal an integer from 1 to 5. In the preferred embodiment, M equals 2. It is desirable for n to equal 2 versus 1 because the chelating ligand is further separated from the antibody and has more rotation. The increased free rotation allows a metal to chelate with the macromolecule more easily.
When n is 3 or greater, the synthesis of the compound becomes lengthy.
Figure 1 illustrates the plcr~llcd reaction pathway or process for forming the compound of this invention. This reaction results in a compound of formula 1, wherein n is 1. If n is to equal 2, an additional methylene group would be present between the alpha amino carbon and the aromatic group. This compound is 2-amino-4-nitrophenylbutyric acid.
The process for synthesizing a compound according to this invention first provides a triamine with a substituent is in the 2-position. The embodiment of Figure 1 has a methylene [n = 1] as the initial substituent for linkage. The preferred embodiment has a phenyleythylene group. The process then provides a tetraaza macromolecule having the substituent in the 2 position. Alkylation with bromoacetic acid forms the four carbon to nitrogen bonds of the carboxymethylene substituents at the R1, R2, R3, and R4 in formula I.
The process of Figure 1 reacts p-nitrophenyl alanine with methanol and hydrochloric acid to form the ester compound 2. This ester is reacted with ethylene~ mine in the presence of triethylamine to remove the hydrochloride salt of the ester formed in the compound. The con(lçn~te of the amide of the ethylene~ mine adduct or compound 3 is subsequently reacted with a diactive ester or compound 6 to form a cyclic product or compound 7.
The desired diactive ester 6 is formed sequentially from amidodiacetic acid for 4 of Figure 1. The amine is first blocked by using the reagent BOC-ON or any other suitable blocking agent, such as FMOC, in the presence of triethylamine which serves to deprotonate the starting material. The subsequent nitrogen-blocked diacetic acid 5 other such nitrogen-blocked compound is then coupled to N-hydroxysuccinimide, or any other suitable compound, such as phenols, or N-hydroxydicarboximides which forms a g reaction ester. The choice of compounds which form active esters or blocking groups is within the scope of the art. The coupling is done by dicyclohexyl-carbodiimide or "DCC".
This step produces the nitrogen-blocked active ester or compound 6.
Ring fommation under high dilution conditions between amino acidamide or compound 3 with the nitrogen-blocked active ester of compound 6 then occurs. This condensing step forms the triamide macrocycle or compound 7. Compound 7 is produced in very high yield. The yield is typically at least about 80 percent. The yield more desirably is between about 80 percent to about 95 percent.
The synthesis of the macrocycle of compound 7 may be accomplished by two pathways. The amine nitrogen of compound 7 is deblocked with trifluoroacetic acid or "TFA". This forms the TFA salt of the triamide macrocycle or compound 8. This compound is reduced with borane/tetrahydrofuran or THF. The resulting borane adduct is cleaved by hydrochloric acid to form the substituted tetr~:~7~m~crocycle of compound 9.
This tetr~7~m~crocycle can then be alkylated with haloacetic acid in the presence of base to fomm a nitroben_yl DOTA or compound 10. Altematively, compound 7 can be reduced with borane/THF and reacted with hydrochloric acid to form compound 9 directly. This altemative pathway produces a slightly poorer yield.
The nitro group of compound 10 can be reduced with hydrogen over pl~tinllm on a carbon catalyst to produce the amino group or the aminoben_yl DOTA depicted as 1 33~0 1 5 compound 11. Compound 11 can then be reacted with thiophosgene to produce the isothiocyanate or compound XII.
The methodology in colurnn 3 of U.S. Patent No. 4,652,519 to Warshawsky et al., provides the methodology to produce the -COOH substituent. This procedure produces the ethylene ~ mine intermediate. The desired intermediate macrocycle is produced by forming the analogous diactive ester of compound 6 by using N, N'-ethylenediaminediacetic acid. Condensation of the ~ rnine with the dinitrogen, diBOC
diactive ester produces diamide intermediary, which is reduced by diborane to produce the ~plo~liate tetraaza macrocycle. The DOTA ligand can be made from this macrocycle.
The synthesis of the X and Z groups are also disclosed by the Warshawsky et al. patent.
The reaction steps described above to produce compounds 10, 11, and 12 are known. The novel feature of the process of Figure 1 is the cyclization procedure. The conversation reaction of compound 4 with compound 6 to form the macrocycle and the full reduction of the macrocycle to produce compound 10 produces the unexpected results of very high yields compound 10.
In its preferred embodiment the coupling of an isothiocyanate chelate of compound 12 of Figure 1 is done by direct conjugation of the isothiocyanate with a free amino group found in many residues of proteins, enzymes or other compounds such as certain hormones. An example of this situation with a hormone is found with the free amino group provided by the epsilon amino group of the lysine or the terminal amino group as the hormone peptide chain. Any free amino group can react with the isothiocyanate to form a thiourea linkage, which is covalently coupled and irreversible. The use of a steroid as a hapten requires that an amino function be present in the steroid.
An advantage of the amine derivative chelate of compound 11 of Figure 1 is that,when coupling to proteins and, in particular, when coupling to antibodies, the carbohydrate of the antibody can be oxidized prior to the coupling reaction. The amine reacts with the aldehyde that is formed on the protein. This aldimine formed can be reduced by cyanoborohydride to form a covalent secondary amine linkage to the antibody in a position that is site-specific. This position is away from the binding site of the FAB'2 part of the monoclonal antibody.
A desirable embodiment of the invention is one having copper metal ion and n is an integer from 2 to 5. This embodiment of the invention can be used to label a monoclonal antibody with Cu67. When n is an integer from 2 to 5, there is less hindrance of the chain of the ligand with the protein than occurs when n is 1. When n is an integer from 2 to 5, sufficient space is provided between the ligand and the protein to allow freer rotation of the ligand. This results in more efficient chelation of the copper ion by the resulting conjugate.
An embodiment of the invention involves a ligand-hapten conjugate of formula 2:
.
'~
Fd. ,~
l .~-- ,~ `I
A . ~ ~
This conjugate chelates metal ions. It is desirable to expose many metals to the protein conjugate in a concentrated metal solution for as short a period of time as possible.
Certain metals, such as divalent metal ions, react rapidly and directly with the conjugate.
The kinetics of the formation reactions for these compounds are so rapid that it is desirable to have the ligand-hapten conjugate available in the pharmacy immediately prior to use.
The conjugate can then be mixed in the radionuclide to form a complex and, subsequently, the metal chelate conjugate formed can be purified by, for example, size exclusion high pressure liquid chromatography. A desirable hapten for the ligand conjugate can be selected from the group consisting of hormones, steroids, enzymes, and proteins.The most commercially useful embodiments of the invention are chelate conjugateshaving formula 1, wherein (1) n is an integer from 1 to 5, (2) X' is a member selected from the group consisting of -NHQ, -NCS-Q, -NHCOCH2-Q, -OCH2COOQ, and -COO-Q
with Q being a hapten selected from the group consisting of hormones, steroids, enzymes, and proteins, and (3) M is a metal ion being a member selected from the group ofelements consisting of Bi, Pb, Y, Cd, Hg, Ac, Th, Sr, and L~nth~nides. These chelates conjugates can deliver radioactive metal ions, such as Pb2l2, Bi2l2, Y90, Th224, and Sr90, to specific cellular disorders.
The preferred embodiment of the invention uses a chelate conjugate binding Pb2l2.
Pb2l2 is a very desirable ph~rm~reutical compound for delivering both beta and alpha radiation to a selected site for treatment of the cellular disorders. The delivery is made through the Pb2'2 ion, which converts with a 10 1/2 hour half-life into Bi2l2. Bi2l2 and ~ ghtf~rs deliver one alpha particle per Pb2l2 nucleus. The desirable result of this chelate conjugate is that the Pb2'2 half-life is sufficient to allow site selection from the body fluid by the hapten before the alpha particle is emitted.
The invention includes a process for treating cellular disorders. This process uses the chelate conjugate with a hapten having a selective binding site at the cellular disorder.
For example, Q can be a monoclonal antibody, wherein the antibody is directed and created against an epitope found specifically on the tumor cells. Thus, when Pb2~2 is transported to the antegen site and, subsequently, decays in secular equilibrium to Bi2l2 and its ~ ghters, a beta irradiation is produced from the lead disintegration. A beta radiation is produced by the bismuth ~ lght~rs. This beta radiation is similar to the beta radiation from Y90 but, in addition, each disintegration of bismuth also produces an alpha particle.
In this manner, a radiotherapy is provided with a radiation dose from both an alpha and a beta particle. If desired, only Bi2l2 can be introduced in those cases where the disorder to be treated, such as with leukemic cells, can be easily reached within the 1 hour half-life of Bi2'2. It is also possible to use this method to treat cancers, where the cells are widely differentiated. This might be preferred where only a long range beta-emitter, such as Y90, is desired. In differing environments, in vivo, the Bi2l2 is retained inside the chelate after the beta emission in differing amounts. Most desirably, at least 95 percent of Bi2l2 remains in the chelate. In an acidic medium, such as the stomach, at least about 70 percent of the . ,~
-14- l 339U 1 5 Bi212 is retained. Retaining at least about 80 or 90 percent, Bi2~2 is also desirable depending on the medium.
The invention includes a process for diagnostic testing. This process uses a chelate conjugate having formula I wherein M is a member selected from the group consisting of Pb , Tc , In ", Ga67, Ga6x, Sc43, Sc44 Fe52 Fe54 Fe56 Fe57 Fe58 d C 55 usefulness of metal ions with both in vitro and in vivo diagnostic procedures is disclosed in U.S. Patent No. 4,454,106.
The most desirable embodiment of this diagnostic process uses Pb203. Pb203 has a52.1 hour half-life as a gamma emitter. Pb203 has a unique property in that it decays at a high percentage only by a single photon emission. This gamma emission is preferred and dominant over all other emissions. This single photon emission makes Pb203 useful for single photon emission computed spectroscopy [SPECT], which is a diagnostic tool. Thus, when Pb203 is linked by use of the chelate to a hapten, which specifically localizes in a tumor, then that particular localization can be three dimensionally mapped for diagnostic purposes in vivo by single photon emission tomography. Alternatively, the emission can be used in vitro in radioimmunoassays.
The procedures and reagents described above for the preferred embodiment of making the compounds are used for this example.
-15- l 33 90 1 5 The antibody specific for the IL-2 antigen is the monoclonal antibody alpha-Tac.This antibody is labelled with the chelate of compound 12 of Figure 1 as follows. The antibody is suspended in a buffered normal saline solution having a pH of about 8.5.
Solid ligand or compound 12 is added to the protein suspension. The protein conjugate forms during reaction overnight and is purified by dialysis against metal-free 0.05 molar citrate/0.15 molar sodium chloride buffer at pH 5.5. Before labelling with metal, the protein is dialyzed against a solution comprising 0.02 molar N-morpholinoethanesulfonic acid and 0.02 molar acetate at pH 5.9.
The protein in solution is labelled with Y90 by reacting with an acetate solution of the isotope followed by passage through a TSK 3000 size exclusion column. This is a high pressure liquid chromotography procedure. The compound is mixed with a pharmaceutical excipient and is used in m~mm~l~ in a therapeutic amount to treat adult T-cell leukemia in m~mm~l~. T-cell leukemia is characterized by extraordinarily large amounts of IL-2 receptors on the tumor cells. The antibody localizes specifically to these tumor cells to deliver its radiation.
EXAMPLES 2 and 3 The procedures and reagents described above for the plefelled embodiment of making the compounds are used for these examples. The only difference between Example 1 and Examples 2 and 3 is the use of the antibody B72.3, which binds specifically to a glycoprotein on LS-174T cells. This glycoprotein is also in humans, who have colon cancer. The model system of this example is an -16- l 3390 1 5 athymic mouse, into which has been implanted LS-174T cells to develop a tumor on the flank of the animal where the cells were implanted. The diagnostic method used to visualize the growing tumor involves the following components. The chelate of compound 12 is first coupled to gadolinium or Pb203 by mixture of the chelate solution at pH 4 to 5 with gadolinium or Pb203 nitrate. This material can be then linked directly to the antibody by mixture to react with the protein and purified according to the method of the previous example.
In Example 2, the gadolinium chelate ligand-protein conjugate is injected or introduced into body fluids of a m~mm~l. The gadolinium then localizes along with the antibody to the tumor and conventional resonance magnetic im:~ging techniques are used to visualize the tumor.
In Example 3, Pb203 is used and the metal-labelled protein conjugate is similarly introduced into the m~mm~l, but gamma camera or SPECT im~gin~ is used to visualize the tumor.
Claims (32)
1. A chelate comprising:
a general formula I:
wherein R1-4 is -CH2COOH;
wherein n is an integer from 1 to 5;
X is a member selected from the group consisting of -NO2, -NH2, -NCS, NHCOCH2-Z with Z being a member selected from the group consisting of Br and I
-OCH2COOH;
-COOH;
and M is a metal ion being a member selected from the group of elements consisting of Bi, Pb, Y, Cd, Hg, Ac, Th, Sr, and Lanthanides.
a general formula I:
wherein R1-4 is -CH2COOH;
wherein n is an integer from 1 to 5;
X is a member selected from the group consisting of -NO2, -NH2, -NCS, NHCOCH2-Z with Z being a member selected from the group consisting of Br and I
-OCH2COOH;
-COOH;
and M is a metal ion being a member selected from the group of elements consisting of Bi, Pb, Y, Cd, Hg, Ac, Th, Sr, and Lanthanides.
2. The chelate of claim 1 wherein n is 1 to 2 and X
is a member selected from the group consisting of -N02, -NCS, and -NHCOCH2-Z with Z being a member selected from the group consisting of Br and I.
is a member selected from the group consisting of -N02, -NCS, and -NHCOCH2-Z with Z being a member selected from the group consisting of Br and I.
3. The chelate of claim 2 wherein M is a member selected from the group consisting of Bi, Pb, Y, Th, Sr, Gd, Eu, and Tb.
4. The chelate of claim 1 wherein n is 2, X is -NCS, and M is a member selected from the group consisting of Pb212, Pb203, Bi212, Y90, Th224, and Sr90.
5. The chelate of claim 4 wherein M is a member selected from the group consisting of Pb212 and Bi212.
6. The chelate of claim 2 wherein n is 2, X is NCS, and M is a member selected from the group consisting of Eu and Tb.
7. A chelate comprising:
a general formula I:
wherein R1-4 is -CH2COOH;
wherein n is an integer from 2 to 5;
X is a member selected from the group consisting of -N02, -NH2, -NCS, -NHCOCH2 - Z with Z being a member selected from the group consisting of Br and I
-COOH;
-OCH2COOH;
and M is Cu.
a general formula I:
wherein R1-4 is -CH2COOH;
wherein n is an integer from 2 to 5;
X is a member selected from the group consisting of -N02, -NH2, -NCS, -NHCOCH2 - Z with Z being a member selected from the group consisting of Br and I
-COOH;
-OCH2COOH;
and M is Cu.
8. The chelate of claim 7 wherein n is 2 and X is a member selected from the group consisting of -N02, -NCS
and -NCOCH2-Z with Z being a member selected from the group consisting of Br and I.
and -NCOCH2-Z with Z being a member selected from the group consisting of Br and I.
9. The chelate of claim 8 wherein X is -NCS.
10. A ligand-hapten conjugate comprising:
a general formula II:
wherein R1-4 is -CH2COOH;
n is an integer from 1 to 5;
X' is a member selected from the group consisting of -NH-Q, with Q being a hapten selected from the group of hormones, steroids, enzymes, and proteins.
a general formula II:
wherein R1-4 is -CH2COOH;
n is an integer from 1 to 5;
X' is a member selected from the group consisting of -NH-Q, with Q being a hapten selected from the group of hormones, steroids, enzymes, and proteins.
11. The ligand conjugate of claim 10 wherein n is 2 and X' is
12. The ligand conjugate of claim 11 wherein Q is a protein, said protein being a monoclonal antibody.
13. A chelate conjugate comprising:
a general formula I:
wherein R1-4 is -CH2COOH;
n is an integer from 1 to 5;
X' is a member selected from the group consisting of -NH-Q, -NHCS-Q, -OCH2COOQ, and with Q being a hapten selected from the group consisting of hormones, steroids, enzymes, and proteins;
M is a metal ion being a member selected from the group of elements consisting of Bi, Pb, Y, Cd, Hg, Ac, Th, Sr, and Lanthanides.
a general formula I:
wherein R1-4 is -CH2COOH;
n is an integer from 1 to 5;
X' is a member selected from the group consisting of -NH-Q, -NHCS-Q, -OCH2COOQ, and with Q being a hapten selected from the group consisting of hormones, steroids, enzymes, and proteins;
M is a metal ion being a member selected from the group of elements consisting of Bi, Pb, Y, Cd, Hg, Ac, Th, Sr, and Lanthanides.
14. The chelate conjugate of claim 13 whereln n is 1 to 2 and X' is
15. The chelate conjugate of claim 14 wherein M is a member selected from the group of Bi, Pb, Y, Th, Sr, Gd, Eu, and Tb
16. The chelate conjugate of claim 15 wherein n is 2 and M is a member selected from the group consisting of Pb212 Pb203, Bi212, Y90, Th224, and Sr90.
17. The chelate conjugate of claim 16 wherein M is a member selected from the group consisting of Pb212 and Bi212
18. The chelate conjugate of claim 15 wherein n is 2 and M is a member selected from the group consisting of Eu and Tb
19. The use of a solution of a metal chelate of formula I:
wherein R1-4 is -CH2COOH;
n is an integer from 1 to 5;
X is a member selected from the group consisting of -NH-Q, -NHcocH2-Q, -NHCOCH2-Q, with Q being a hapten selected from the group consisting of hormones, steroids, enzymes, and proteins, M is a metal ion being a member selected from the group of elements consisting of Bi, Pb, Y, and Gd for preparing a pharmaceutical composition for treating cellular disorders.
wherein R1-4 is -CH2COOH;
n is an integer from 1 to 5;
X is a member selected from the group consisting of -NH-Q, -NHcocH2-Q, -NHCOCH2-Q, with Q being a hapten selected from the group consisting of hormones, steroids, enzymes, and proteins, M is a metal ion being a member selected from the group of elements consisting of Bi, Pb, Y, and Gd for preparing a pharmaceutical composition for treating cellular disorders.
20. The use of claim 19 wherein n is 2, X is , and M is Gd.
21. The use of claim 19 wherein M is Pb212, said Pb212 converts to Bi212 and daughters thereof, said Bi212 emits an alpha particle to treat said cellular disorders.
22. The use of claim 21 wherein n is 2 and X is .
23. The use of claim 22 wherein at least 70 percent of said Bi212 remains in said chelate.
24. The use of claim 23 wherein at least 80 percent of said Bi212 remains in said chelate.
25. The use of claim 24 wherein at least 90 percent of said Bi212 remains in said chelate.
26. The use of claim 25 wherein at least 95 percent of said Bi212 remains in said chelate.
27. A process for diagnostic testing comprising ?ministering to a mammal a metal chelate ligand ?njugate of the general formula I:
wherein R1-4 is -CH2COOH;
n is an integer from 1 to 5;
X' is a member selected from the group consisting of -NH-Q, , -NHCOCH2-Q, -OCH2COOQ, and with Q being a hapten selected from the group consisting of hormones, steroids, enzymes, and proteins;
M is a metal ion being a member selected from the group consisting of Pb203, Tc99m, In111, Ga67, Ga68, Sc43, Sc44, Fe52, Fe54, Fe56, Fe57, Fe58, and Co55, and detecting the presence of any bound metal chelate ligand conjugate.
wherein R1-4 is -CH2COOH;
n is an integer from 1 to 5;
X' is a member selected from the group consisting of -NH-Q, , -NHCOCH2-Q, -OCH2COOQ, and with Q being a hapten selected from the group consisting of hormones, steroids, enzymes, and proteins;
M is a metal ion being a member selected from the group consisting of Pb203, Tc99m, In111, Ga67, Ga68, Sc43, Sc44, Fe52, Fe54, Fe56, Fe57, Fe58, and Co55, and detecting the presence of any bound metal chelate ligand conjugate.
28. The process of claim 27 wherein n is 2, X is -NCS-Q, and Q is a monoclonal antibody.
29. The process of claim 28 wherein M is Pb203.
30. A pharmaceutical composition for treating cellular disorders comprising a solution of a metal chelate of general formula I:
wherein R1-4 is -CH2COOH;
n is an integer from 1 to 5;
X is a member selected from the group consisting of -NH-Q, , -NHCOCH2-Q, -OCH2COOQ, with Q being a hapten selected from the group consisting of hormones, steroids, enzymes, and proteins;
M is a metal ion being a member selected from the group of elements consisting of Bi, Pb, Y, and Gd.
wherein R1-4 is -CH2COOH;
n is an integer from 1 to 5;
X is a member selected from the group consisting of -NH-Q, , -NHCOCH2-Q, -OCH2COOQ, with Q being a hapten selected from the group consisting of hormones, steroids, enzymes, and proteins;
M is a metal ion being a member selected from the group of elements consisting of Bi, Pb, Y, and Gd.
31. The use of a metal chelate of a general formula I:
wherein R1-4 is -CH2COOH;
n is an integer from 1 to 5;
X is a member selected from the group consisting of -NH-Q, , -NHCOCH2-Q, -OCH2COOQ, , with Q being a hapten selected from the group consisting of hormones, steroids, enzymes, and proteins;
M is a metal ion being a member selected from the group of elements consisting of Bi, Pb, Y, and Gd, as a cellular disorder treatment agent.
wherein R1-4 is -CH2COOH;
n is an integer from 1 to 5;
X is a member selected from the group consisting of -NH-Q, , -NHCOCH2-Q, -OCH2COOQ, , with Q being a hapten selected from the group consisting of hormones, steroids, enzymes, and proteins;
M is a metal ion being a member selected from the group of elements consisting of Bi, Pb, Y, and Gd, as a cellular disorder treatment agent.
32. The use of a metal chelate of a general formula I:
wherein R1-4 is -CH2COOH;
n is an integer from 1 to 5;
X is a member selected from the group consisting of -NH-Q, , -NHCOCH2-Q, -OCH2COOQ, with Q being a hapten selected from the group consisting of hormones, steroids, enzymes, and proteins;
M is a metal ion being a member selected from the group of elements consisting of Bi, Pb, Y, and Gd, for use in the manufacture of a medicament for the treatment of a cellular disorder.
wherein R1-4 is -CH2COOH;
n is an integer from 1 to 5;
X is a member selected from the group consisting of -NH-Q, , -NHCOCH2-Q, -OCH2COOQ, with Q being a hapten selected from the group consisting of hormones, steroids, enzymes, and proteins;
M is a metal ion being a member selected from the group of elements consisting of Bi, Pb, Y, and Gd, for use in the manufacture of a medicament for the treatment of a cellular disorder.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19853888A | 1988-05-25 | 1988-05-25 | |
| US198,538 | 1988-05-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1339015C true CA1339015C (en) | 1997-03-25 |
Family
ID=22733797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000600714A Expired - Fee Related CA1339015C (en) | 1988-05-25 | 1989-05-25 | Macrocyclic chelates and methods of use thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5428154A (en) |
| EP (1) | EP0416033B1 (en) |
| JP (2) | JPH0720989B2 (en) |
| AT (1) | ATE134999T1 (en) |
| AU (2) | AU630362B2 (en) |
| CA (1) | CA1339015C (en) |
| DE (1) | DE68925904T2 (en) |
| IL (1) | IL90409A (en) |
| WO (1) | WO1989011475A1 (en) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8719042D0 (en) * | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
| AU634167B2 (en) * | 1988-06-24 | 1993-02-18 | Dow Chemical Company, The | Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates |
| GB9111199D0 (en) * | 1991-05-23 | 1991-07-17 | Sandoz Ltd | Improvements in or relating to organic compounds |
| US6139603A (en) * | 1989-02-22 | 2000-10-31 | L'air Liquide, Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude | Process for recovering oxygen |
| US5292868A (en) * | 1989-05-26 | 1994-03-08 | Akzo N.V. | Chelating agents for attaching metal ions to proteins |
| JPH04154729A (en) * | 1990-10-16 | 1992-05-27 | Nippon Mejifuijitsukusu Kk | Contrast medium for nuclear magnetic resonance |
| US6403771B1 (en) | 1991-02-19 | 2002-06-11 | Actinium Pharmaceuticals, Limited | Method and means for site directed therapy |
| US5541287A (en) * | 1992-06-09 | 1996-07-30 | Neorx Corporation | Pretargeting methods and compounds |
| US6022966A (en) * | 1993-11-22 | 2000-02-08 | Neorx Corporation | Pretargeting methods and compounds |
| CA2100709C (en) * | 1992-07-27 | 2004-03-16 | Maurits W. Geerlings | Method and means for site directed therapy |
| EP0955066A3 (en) * | 1992-07-31 | 2002-08-28 | Australian Nuclear Science And Technology Organisation | Metal complexes of hydroxyaryl containing aminocarboxylic acid chelating agents |
| US5807535A (en) * | 1992-07-31 | 1998-09-15 | Australian Nuclear Science & Technology Organisation | Metal complexes of hydroxyaryl containing aminocarboxylic acid chelating agents |
| US5650134A (en) * | 1993-01-12 | 1997-07-22 | Novartis Ag (Formerly Sandoz Ltd.) | Peptides |
| AU7384394A (en) * | 1993-06-30 | 1995-01-24 | Akzo Nobel N.V. | Chelating compounds |
| WO1995019187A1 (en) * | 1994-01-12 | 1995-07-20 | Amersham International Plc | Biological targeting agents |
| US6693190B1 (en) | 1994-05-11 | 2004-02-17 | Bracco International B.V. | Enhanced relaxivity monomeric and multimeric compounds |
| GB9417873D0 (en) * | 1994-09-06 | 1994-10-26 | Sandoz Ltd | Organic compounds |
| US6770261B2 (en) * | 1995-06-02 | 2004-08-03 | Research Corporation Technologies | Magnetic resonance imaging agents for the detection of physiological agents |
| US5814521A (en) * | 1995-10-06 | 1998-09-29 | Bayer Corporation | Metal ion determination by sandwich aggregation assay |
| US6713046B1 (en) * | 1997-10-27 | 2004-03-30 | Research Corporation Technologies | Magnetic resonance imaging agents for the delivery of therapeutic agents |
| AU752812B2 (en) | 1997-11-17 | 2002-10-03 | Research Corporation Technologies, Inc. | Magnetic resonance imaging agents for the detection of physiological agents |
| US6372187B1 (en) | 1998-12-07 | 2002-04-16 | Mcdermott Technology, Inc. | Alkaline sorbent injection for mercury control |
| MY133346A (en) * | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
| US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
| US6855859B2 (en) * | 1999-03-31 | 2005-02-15 | The Babcock & Wilcox Company | Method for controlling elemental mercury emissions |
| US6328939B1 (en) | 1999-03-31 | 2001-12-11 | Mcdermott Technology, Inc. | Mercury removal in utility wet scrubber using a chelating agent |
| US6284199B1 (en) * | 1999-03-31 | 2001-09-04 | Mcdermott Technology, Inc. | Apparatus for control of mercury |
| US6680993B2 (en) | 1999-11-30 | 2004-01-20 | Stanley Satz | Method of producing Actinium-225 and daughters |
| HUP0203743A2 (en) * | 2000-02-25 | 2003-02-28 | R Keith Frank | Actinium-225 complexes and conjugates for radioimmunotherapy |
| LU90544B1 (en) * | 2000-03-14 | 2001-09-17 | Europ Economic Community | Bifunctional chelating agent |
| US6565828B2 (en) | 2000-04-07 | 2003-05-20 | Bristol-Myers Squibb Company | Macrocyclic chelants for metallopharmaceuticals |
| AU2002211232B2 (en) * | 2000-09-15 | 2006-10-19 | Sloan Kettering Institute For Cancer Research | Targeted alpha particle therapy using actinium-225 conjugates |
| US6517814B2 (en) | 2001-01-09 | 2003-02-11 | Bristol-Myers Squibb Pharma Company | Macrocyclic chelants useful for metallopharmaceuticals |
| CN1622832A (en) * | 2001-02-23 | 2005-06-01 | 布里斯托尔-迈尔斯斯奎布药品公司 | Labeled macrophage scavenger receptor antagonists for imaging atherosclerosis and vulnerable plaque |
| US20030004236A1 (en) * | 2001-04-20 | 2003-01-02 | Meade Thomas J. | Magnetic resonance imaging agents for detection and delivery of therapeutic agents and detection of physiological substances |
| US20030135108A1 (en) * | 2001-05-02 | 2003-07-17 | Silva Robin M. | High throughput screening methods using magnetic resonance imaging agents |
| US20020197648A1 (en) * | 2001-05-02 | 2002-12-26 | Silva Robin M. | High throughput screening methods using magnetic resonance imaging agents |
| EP1420688A4 (en) * | 2001-06-25 | 2005-08-31 | Us Gov Health & Human Serv | Macromolecular imaging agents for liver imaging |
| US20030198597A1 (en) * | 2002-04-22 | 2003-10-23 | Meade Thomas J. | Novel macrocyclic activatible magnetic resonance imaging contrast agents |
| US20030086868A1 (en) * | 2002-08-12 | 2003-05-08 | Dangshe Ma | Actinium-225 complexes and conjugates for radioimmunotherapy |
| AU2003270347B2 (en) * | 2002-09-06 | 2007-05-24 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Backbone-substituted bifunctional dota ligands, complexes and compositions thereof, and methods of using same |
| EP1551292B1 (en) | 2002-09-24 | 2016-04-27 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Imaging method for convection enhanced delivery of therapeutic agents |
| GB0308731D0 (en) * | 2003-04-15 | 2003-05-21 | Anticancer Therapeutic Inv Sa | Method of radiotherapy |
| DK1706452T3 (en) | 2003-12-30 | 2009-01-19 | Univ California Office Of The | Aromatic triamide-lanthanide complexes |
| US20050171424A1 (en) * | 2004-01-13 | 2005-08-04 | The Gov. Of The Usa As Rep. By The Secretary Of The Dept. Of Health And Human Services | Methods for imaging the lymphatic system using dendrimer-based contrast agents |
| CA2581639C (en) * | 2004-09-30 | 2016-07-26 | Molecular Devices Corporation | Luminescent lanthanide complexes |
| US20060204443A1 (en) * | 2005-03-11 | 2006-09-14 | The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services | Methods for tumor treatment using dendrimer conjugates |
| US20070025910A1 (en) | 2005-07-29 | 2007-02-01 | Norenberg Jeffrey P | Anticancer therapy |
| EP2044090B1 (en) | 2006-07-10 | 2015-04-08 | The Regents of The University of California | Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides |
| CA2660800C (en) | 2006-08-15 | 2016-03-01 | The Regents Of The University Of California | Luminescent macrocyclic lanthanide complexes |
| US8388936B2 (en) * | 2008-02-22 | 2013-03-05 | Mcw Research Foundation, Inc. | In vivo mitochondrial labeling using positively-charged nitroxide enhanced and gadolinium chelate enhanced magnetic resonance imaging |
| US8388931B2 (en) | 2008-02-29 | 2013-03-05 | Marcos Lopez | 99m Tc-labeled triphenylphosphonium derivative contrasting agents and molecular probes for early detection and imaging of breast tumors |
| US8440827B2 (en) * | 2008-07-31 | 2013-05-14 | Duke University | Photolabile caged transition metal complexes and methods of using the same |
| RU2704802C2 (en) | 2009-07-22 | 2019-10-31 | Актиниум Фармасьютикалз Инк. | Methods for producing radioimmunoconjugates |
| WO2011025790A1 (en) | 2009-08-24 | 2011-03-03 | Lumiphore, Inc. | Macrocyclic hopo chelators |
| GB201002508D0 (en) | 2010-02-12 | 2010-03-31 | Algeta As | Product |
| KR101253100B1 (en) * | 2010-02-16 | 2013-04-10 | 경북대학교 산학협력단 | Polyazamacrocyclic compounds, producing method and biomedical application thereof |
| US11453652B2 (en) | 2013-03-15 | 2022-09-27 | Lumiphore, Inc. | Di-macrocycles |
| FR3006688B1 (en) * | 2013-06-06 | 2015-08-14 | Centre Nat Rech Scient | LEAD (II) AND BISMUTH (III) CHELATES OF TETRAAZACYCLOALCANES TRANS-DI-N-PICOLINATES |
| ES2784684T3 (en) * | 2015-02-26 | 2020-09-29 | Sciencons AS | Radiopharmaceutical solutions with advantageous properties |
| CN105807055B (en) * | 2016-03-15 | 2017-10-10 | 中国烟草总公司郑州烟草研究院 | A kind of test strips for detecting dichloro quinolinic acid and its preparation method and application |
| EP3409297A1 (en) | 2017-05-30 | 2018-12-05 | AlfaRim Medial Holding B.V. | The optimal 225actinium--213bismuth generator for alpha-particle radioimmunotherapy |
| WO2019057598A1 (en) | 2017-09-20 | 2019-03-28 | Alfarim Medical Holding B.V. | The optimal 225actinium--213bismuth generator for alpha-particle radioimmunotherapy |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2186464A (en) * | 1939-10-18 | 1940-01-09 | Alframine Corp | Condensation product and method of preparing same |
| US3860576A (en) * | 1972-04-26 | 1975-01-14 | Dow Chemical Co | N-substituted-tetra-azacyclotetradecanes |
| US3936445A (en) * | 1973-07-04 | 1976-02-03 | Badische Anilin- & Soda-Fabrik Aktiengesellschaft | Process for the production of iron complexes of tetraazaannulenes |
| US3979379A (en) * | 1975-04-25 | 1976-09-07 | The United States Of America As Represented By The Secretary Of The Army | Process for producing 1,3,5,7-tetraalkanoyl-1,3,5,7-octahydrotetrazocines |
| DE2803528C2 (en) * | 1977-03-09 | 1984-10-18 | Tabushi, Iwao, Kyoto | Heavy metal ion adsorbent and its use to adsorb heavy metal ions |
| JPS53144592A (en) * | 1977-05-19 | 1978-12-15 | Tabuse Iwao | 122alkyll1*4*7*100tetrazacyclotridecane |
| GB1529150A (en) * | 1977-05-17 | 1978-10-18 | Tabushi I | Alkyl substituted cyclic alkyltetramines |
| US4543213A (en) * | 1978-07-24 | 1985-09-24 | The United States Of America As Represented By The United States Department Of Energy | Process for preparing 2,3-dihydroxybenzoic acid amides of tetraazaalkanes and cycloalkanes |
| US4578517A (en) * | 1983-09-16 | 1986-03-25 | Air Products And Chemicals, Inc. | Polyalkylene polyamines from alkanolamine and ammonia or amines using group IIIB metal acid phosphate catalysts |
| JPS61226751A (en) * | 1985-03-30 | 1986-10-08 | Konishiroku Photo Ind Co Ltd | Solution for processing silver halide photographic material and its processing method |
| US4678667A (en) * | 1985-07-02 | 1987-07-07 | 501 Regents of the University of California | Macrocyclic bifunctional chelating agents |
| US4885363A (en) * | 1987-04-24 | 1989-12-05 | E. R. Squibb & Sons, Inc. | 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
| GB8603537D0 (en) * | 1986-02-13 | 1986-03-19 | Parker D | Conjugate compound |
| DE3625417C2 (en) * | 1986-07-28 | 1998-10-08 | Schering Ag | Tetraazacyclododecane derivatives |
| US5132409A (en) * | 1987-01-12 | 1992-07-21 | Bracco Industria Chimica S.P.A. | Macrocyclic chelating agents and chelates thereof |
| US5049667A (en) * | 1987-04-14 | 1991-09-17 | Guerbet S.A. | Nitrogen-containing cyclic ligands |
| DE3713842A1 (en) * | 1987-04-22 | 1988-11-17 | Schering Ag | SUBSTITUTED CYCLIC COMPLEX MAKERS, COMPLEX AND COMPLEX SALTS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENTS CONTAINING THEM |
| US5064956A (en) * | 1987-06-24 | 1991-11-12 | The Dow Chemical Company | Process for preparing mono-n-alkylated polyazamacrocycles |
| GB8719042D0 (en) * | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
| US4923985A (en) * | 1988-05-25 | 1990-05-08 | The United States Of America As Represented By The Department Of Health & Human Services | Process for synthesizing macrocyclic chelates |
| US4987227A (en) * | 1988-10-21 | 1991-01-22 | The Research Foundation Of State University Of New York | Polyazamacrocycles and their metal complexes |
| US5053503A (en) * | 1989-02-17 | 1991-10-01 | Centocor | Chelating agents |
-
1989
- 1989-05-24 EP EP89907438A patent/EP0416033B1/en not_active Expired - Lifetime
- 1989-05-24 WO PCT/US1989/002201 patent/WO1989011475A1/en active IP Right Grant
- 1989-05-24 AT AT89907438T patent/ATE134999T1/en not_active IP Right Cessation
- 1989-05-24 JP JP1507105A patent/JPH0720989B2/en not_active Expired - Fee Related
- 1989-05-24 DE DE68925904T patent/DE68925904T2/en not_active Expired - Fee Related
- 1989-05-24 AU AU38428/89A patent/AU630362B2/en not_active Ceased
- 1989-05-25 IL IL9040989A patent/IL90409A/en active IP Right Grant
- 1989-05-25 CA CA000600714A patent/CA1339015C/en not_active Expired - Fee Related
-
1993
- 1993-01-28 AU AU32108/93A patent/AU655704B2/en not_active Ceased
- 1993-10-22 US US08/140,714 patent/US5428154A/en not_active Expired - Lifetime
-
1994
- 1994-07-11 JP JP6181867A patent/JP2582341B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU655704B2 (en) | 1995-01-05 |
| EP0416033B1 (en) | 1996-03-06 |
| JPH07258281A (en) | 1995-10-09 |
| JPH03503531A (en) | 1991-08-08 |
| US5428154A (en) | 1995-06-27 |
| AU630362B2 (en) | 1992-10-29 |
| JP2582341B2 (en) | 1997-02-19 |
| WO1989011475A1 (en) | 1989-11-30 |
| DE68925904D1 (en) | 1996-04-11 |
| AU3210893A (en) | 1993-04-01 |
| IL90409A0 (en) | 1990-01-18 |
| ATE134999T1 (en) | 1996-03-15 |
| IL90409A (en) | 1996-09-12 |
| AU3842889A (en) | 1989-12-12 |
| EP0416033A1 (en) | 1991-03-13 |
| DE68925904T2 (en) | 1996-10-31 |
| EP0416033A4 (en) | 1991-04-17 |
| JPH0720989B2 (en) | 1995-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1339015C (en) | Macrocyclic chelates and methods of use thereof | |
| US5583219A (en) | Macrocyclic chelating agent | |
| JP3292301B2 (en) | Complexing agents and targeting radioimmunological reagents useful in therapeutic and diagnostic imaging compositions and methods | |
| US4923985A (en) | Process for synthesizing macrocyclic chelates | |
| JP2555391B2 (en) | Main chain polysubstituted chelates for forming metal chelate-protein complexes | |
| US7081452B2 (en) | Scorpionate-like pendant macrocyclic ligands, complexes and compositions thereof, and methods of using same | |
| CA2495442C (en) | Backbone-substituted bifunctional dota ligands, complexes and compositions thereof, and methods of using same | |
| AU638757B2 (en) | Chelating agents for attaching metal ions to proteins | |
| CA2079206A1 (en) | Fonctionalized complexand | |
| IL113068A (en) | Ligand-hapten conjugates of 1,4,7,10-tetraazacyclo-dodecane-n,n'n'',n"'-tetraacetic acid | |
| JPH05320147A (en) | Pendant-type bifunctional macrocyclic chelate ligand, its production and metal complex | |
| JP2962883B2 (en) | New macrocyclic chelating ligands and their metal complexes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKLA | Lapsed |
Effective date: 20130325 |